pdufa.bio

Annamycin

Page updated ·next FDA decision on the calendar ·Data as of Nov 5, 2026 9:00 PM ET

Annamycin is a Moleculin Biotech, Inc. program. Its next catalyst is a Readout in Q1 2027. Every date links its source.

MBRX catalyst hub

All upcoming FDA decision dates on the 2026 PDUFA calendar

About this program

Sponsor: Moleculin Biotech, Inc. (MBRX). We track 1 catalyst event for this program: 1 upcoming and 0 in the record. A PDUFA date is the FDA's target date to complete review of a marketing application; a readout is the sponsor's expected date for clinical trial results. What a PDUFA date is · why we do not compare trial results across drugs.

Catalyst history

Readout · Q1 2027MBRX

Questions

When is Annamycin's next FDA decision or readout?

The next tracked catalyst for Annamycin is a Readout in Q1 2027.

What happened at Annamycin's most recent FDA decision?

No FDA decision for Annamycin is in our archive yet.

Who makes Annamycin?

Moleculin Biotech, Inc. (MBRX).

Where does this data come from?

FDA announcements, sponsor press releases and SEC filings; every date on this page links its source.